Latest news
FDA completes review of NRx Pharmaceuticals preservative-free ketamine ANDA - TipRanksTipRanks · Fri, 07 Aug 2026 19:39:14 GMTNRx Pharmaceuticals Shares Rise as FDA Completes Initial Review of Ketamine Product - citybizcitybiz · Fri, 07 Aug 2026 18:01:20 GMTNRx Pharma rises on FDA review of ketamine ANDA (NRXP:NASDAQ) - Seeking AlphaSeeking Alpha · Fri, 07 Aug 2026 17:08:38 GMTFDA Clears Major Regulatory Hurdle as Preservative-Free Ketamine Program Moves Within Reach of Commercialization: NRx Pharmaceuticals: (NAS DAQ: NRXP) - PRLogPRLog · Fri, 07 Aug 2026 13:50:38 GMTFDA Completes First-Cycle Review of Preservative-Free - GlobeNewswireGlobeNewswire · Fri, 07 Aug 2026 11:00:00 GMTA vial used in products that shipped 11.9M doses remains in NRx's FDA review - Stock TitanStock Titan · Fri, 07 Aug 2026 11:00:00 GMTKetamine Therapy Market to Reach USD 8.8 Billion by 2034 at 15.00% CAGR - SRI - openPR.comopenPR.com · Fri, 07 Aug 2026 10:17:17 GMTBetter U Expands 2026 Patient Eligibility, Safety and Treatment Access Information for At-Home Ketamine Therapy - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 23:57:30 GMT